Connect with us

Hi, what are you looking for?

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq:BPTH)

DALLAS, TX — September 30, 2022 —  Bio-Path Holdings, Inc. (Nasdaq:BPTH): The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q2FY22.pdf

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Bio-Path’s pipeline continues to expand with new cancer indications
  • Bio-Pathhas completed Phase 1 clinical trials for its lead candidate prexigebersen for AML and other blood cancers
  • The Company most recently reported that cash on hand as of 6/30/22 is sufficient to fund operations according to plan for at the next 12 months

Click image above to view full announcement.


About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.

Contacts:

Stonegate Capital Partners
(214) 987-4121
[email protected]

Source: Stonegate, Inc.

Distributed by: Reportable, Inc.

Written By

You may also like:

Business

It’s long been proven that British workers put in some of the longest weekly hours at work.

Business

As CIO, my office shapes every employee's experience from the first day.

Business

A phosphate facility operated by Morocco's state-owned OCP near Laayoune in the disputed Western Sahara - Copyright AFP/File Fadel SENNAIsmail BELLAOUALIA global fertiliser supply...

Business

Amid economic gloom fuelled by soaring inflation and fears of China's weaker energy demand, the two global crude benchmarks remain close to their lowest level...